Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Hedgehog Proteins
  • Neoplasms
  • Signal Transduction
  • Veratrum Alkaloids

abstract

  • IPI-926 was well tolerated up to 160 mg QD within 28-day cycles, which was established as the recommended phase II dose and schedule for this agent. Single-agent activity of IPI-926 was observed in HhP inhibitor-na├»ve patients with BCC.

publication date

  • May 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3694426

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-3654

PubMed ID

  • 23575478

Additional Document Info

start page

  • 2766

end page

  • 74

volume

  • 19

number

  • 10